Do you have a relative with Alzheimers Disease

Here are the Treatment options avilable
Donepezil is the most commonly prescribed anti-dementia therapy in the world. In the initial clinical trials, both 5 mg and 10 mg daily doses were equally effective in improving cognitive and functional ability of individuals with mild and moderate Alzheimer disease over 3 months to 6 months. Recent evidence suggests that donepezil maintains cognitive test scores at or above baseline for a period of 9 months to 12 months and is superior to placebo for more than one year
Rivastigmine is a carbamate derived cholinesterase inhibitor. As a newer agent, somewhat less published information and treatment experience is available. It has shown efficacy for improving cognition, behavior, and function similar to that reported for donepezil. A dose-dependent response occurs with the greatest efficacy at highest doses, but tolerability at those dose ranges is sometimes problematic
Galantamine has acetylcholinesterase activity and may also have a direct facilitative effect on nicotinic ACh receptors. As with rivastigmine, clinical experience is limited, in comparison to donepezil and tacrine. The clinical trials experience suggests cognitive, behavioral, and functional effects similar in magnitude to other cholinesterase inhibitors
The preceding drugs are considered cognitive-enhancing agents, but are not known to affect the underlying mechanisms of cell death in Alzheimer disease. Other agents have been studied for their ability to slow the progression of Alzheimer disease by altering the rate of neuronal death. The antioxidant compounds vitamin E (alpha-tocopherol) and selegiline have been reported to slow the progress of moderately severe Alzheimer disease, without improving cognitive ability
Noncognitive symptoms are often a greater source of caregiver difficulty than the memory loss. These are usually treated with conventional psychotropic agents such as neuroleptics, antidepressants, and anxiolytics. Cholinesterase inhibitors can also alleviate noncognitive symptoms, with the greatest effect in moderately affected individuals